Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer

By rosaguerrero • July 20, 2022

Shin DS, Park K, Garon E, Dubinett S. Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer. Semin Oncol. 2022 Jul 2:S0093-7754(22)00045-8. doi: 10.1053/j.seminoncol.2022.06.005. Epub ahead of print. PMID: 35851153.

Tags: EZH2, Hematology/Oncology, immunotherapy, Lung cancer, PD-1 blockade, PRC2, Pulmonary, Critical Care & Sleep Medicine, Veterans Administration

Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma

Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K,[...]

Biology, care, and outcomes of gestational breast cancers: a review

Duggirala N, Zhang S, Master A, Rao R, Kapoor NS, Bardia A, Lipsyc-Sharf M. Biology, care, and outcomes of gestational breast cancers: a review. Breast[...]

Yoo C, Ueno M, Klümpen HJ, Kelley RK, Vogel A, Furuse J, Ren Z, Yau T, Chan SL, Ozaka M, Oh SC, Gu S, Park[...]